{"title":"Computer-integrated drug design provides new leads for thromboembolic disorders","authors":"Anya M Hillery","doi":"10.1016/S1461-5347(00)00257-1","DOIUrl":"10.1016/S1461-5347(00)00257-1","url":null,"abstract":"","PeriodicalId":80125,"journal":{"name":"Pharmaceutical science & technology today","volume":"3 4","pages":"Pages 114-115"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00257-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21604918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Live bacterial vectors for intranasal delivery of protective antigens","authors":"Camille Locht","doi":"10.1016/S1461-5347(00)00256-X","DOIUrl":"10.1016/S1461-5347(00)00256-X","url":null,"abstract":"<div><p><span><span><span>To exploit the advantages of mucosal, particularly intranasal, vaccination, several live bacterial vectors<span> have been developed and shown to elicit strong immune responses, including protective immunity against viruses, bacteria or parasites. Two main categories can be distinguished; those that are based on commensal bacteria, such as lactococci, </span></span>lactobacilli<span> or certain streptococci and </span></span>staphylococci, and those that are based on attenuated pathogens, such as </span><em>Salmonella</em><span>, BCG and </span><span><em>Bordetella</em></span>. The quality of the immune responses may vary between the vector systems, but in most cases the immune responses obtained after intranasal administration are stronger than those obtained after oral administration of the same vaccines.</p></div>","PeriodicalId":80125,"journal":{"name":"Pharmaceutical science & technology today","volume":"3 4","pages":"Pages 121-128"},"PeriodicalIF":0.0,"publicationDate":"2000-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00256-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21604920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recombinant in vitro tools to predict drug metabolism and safety","authors":"Thomas Friedberg","doi":"10.1016/S1461-5347(00)00243-1","DOIUrl":"10.1016/S1461-5347(00)00243-1","url":null,"abstract":"<div><p>Drug metabolism determines several pharmacological and toxicological properties of pharmaceuticals and is catalysed by drug metabolizing enzymes<span>. Prediction of drug metabolism in humans based on animal experiments is complicated by species differences in the catalytic properties of these enzymes. This review describes and evaluates the use of recombinant models that contain human drug metabolizing enzymes to facilitate the prediction of pharmacokinetic properties of candidate drugs in humans.</span></p></div>","PeriodicalId":80125,"journal":{"name":"Pharmaceutical science & technology today","volume":"3 3","pages":"Pages 99-105"},"PeriodicalIF":0.0,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00243-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21558828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew W Lloyd (Monitor editor), A.Christy Hunter (Monitor editor)
{"title":"Monitor: progress and profiles","authors":"Andrew W Lloyd (Monitor editor), A.Christy Hunter (Monitor editor)","doi":"10.1016/S1461-5347(00)00246-7","DOIUrl":"10.1016/S1461-5347(00)00246-7","url":null,"abstract":"<div><p><em>Monitor</em> provides an insight into the latest developments in pharmaceutical science and technology through brief synopses of recent presentations, publications and patents, and expert commentaries on the latest technologies. There are two sections: <em>Progress</em> summarizes the latest developments in pharmaceutical process technology, formulation, analytical technology, sterilization, controlled drug delivery systems and regulatory issues; <em>Profiles</em> offers expert commentary on emerging technologies, novel processes and strategic, organizational and logistic issues underlying pharmaceutical R&D.</p></div>","PeriodicalId":80125,"journal":{"name":"Pharmaceutical science & technology today","volume":"3 3","pages":"Pages 106-110"},"PeriodicalIF":0.0,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00246-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21558829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The importance of drug delivery systems in tissue engineering","authors":"Yasuhiko Tabata","doi":"10.1016/S1461-5347(00)00242-X","DOIUrl":"10.1016/S1461-5347(00)00242-X","url":null,"abstract":"<div><p>Tissue engineering is designed to regenerate natural tissues or to create biological substitutes for defective or lost tissues and organs through the use of cells. In addition to cells and their scaffolds, growth factors are required to promote tissue regeneration. Indeed, growth factor-induced vascularization is effective in supplying the oxygen and nutrients necessary for the survival of transplanted cells in organ substitution. However, growth factors have poor <em>in vivo</em> stability and so the biological effects are often unpredictable unless the delivery system is contrived. This review provides several examples to emphasize the importance of drug delivery systems in tissue engineering.</p></div>","PeriodicalId":80125,"journal":{"name":"Pharmaceutical science & technology today","volume":"3 3","pages":"Pages 80-89"},"PeriodicalIF":0.0,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00242-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21559591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Serengulam V Govindan , David M Goldenberg , Hans J Hansen , Gary L Griffiths
{"title":"Advances in the use of monoclonal antibodies in cancer radiotherapy","authors":"Serengulam V Govindan , David M Goldenberg , Hans J Hansen , Gary L Griffiths","doi":"10.1016/S1461-5347(00)00241-8","DOIUrl":"10.1016/S1461-5347(00)00241-8","url":null,"abstract":"<div><p><span>The use of monoclonal antibodies<span><span> (MAbs) as radiation carriers in argeted radiotherapy of cancers has produced striking clinical responses in hematologic diseases, such as non-Hodgkin’s lymphoma. Novel strategies are currently being examined in an effort to improve efficacy in </span>solid tumor therapies. Two of these strategies involve minimizing the systemic toxicity of a circulating </span></span>radionuclide via ‘pretargeting’, and the sensitization of tumors to radiation by combination therapy with radiosensitizing drugs. Advances made in radiolabeling chemistries and in the use of alpha-particle emitters can also improve utility. Clinical evidence suggests that radioimmunotherapy may be best applied in minimal-disease and adjuvant settings in combination with other cancer therapy modalities.</p></div>","PeriodicalId":80125,"journal":{"name":"Pharmaceutical science & technology today","volume":"3 3","pages":"Pages 90-98"},"PeriodicalIF":0.0,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1461-5347(00)00241-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21559594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
